Synopsis

Source of validity: Scientific
Rating (out of 5): 2

N-Acetyl Cysteine (NAC) has been investigated for its potential role in mitigating radiation sickness, primarily due to its antioxidant properties and its ability to replenish intracellular glutathione. Preclinical studies, including animal models, have suggested that NAC can ameliorate tissue damage following exposure to ionizing radiation by scavenging free radicals and reducing oxidative stress, one of the principal mechanisms of radiation-induced cellular injury. For example, research published in Radiation Research and other peer-reviewed journals has shown that NAC administration before or shortly after radiation exposure can reduce mortality and tissue injury in rodents.

However, clinical data in humans are extremely limited. Most evidence comes from in vitro experiments or animal studies, and there are few, if any, well-controlled human trials directly evaluating NAC as a treatment for acute radiation sickness. Some case reports and small series have suggested possible benefits for related conditions, such as reducing side effects of radiation therapy in cancer patients, but not for acute high-dose exposures typical of radiation accidents.

In summary, while there is a scientific basis (preclinical) for the use of NAC in radiation exposure scenarios, the quality and quantity of human evidence are low. NAC is not part of standard clinical protocols for radiation sickness, and its use for this purpose is considered experimental. More research, especially in humans, is necessary to establish efficacy and safety for this indication.

More about N-Acetyl Cysteine
More about Radiation Sickness

Other ingredients used for Radiation Sickness

Other health conditions supported by N-Acetyl Cysteine

Products containing N-Acetyl Cysteine